What were the key takeaways from Hims & Hers Health's earnings call?

What guidance did Hims & Hers Health's management provide for the next earnings period?

Did Hims & Hers Health beat or miss consensus estimates last quarter?

What is Hims & Hers Health's latest dividend and current dividend yield?

What factors drove the changes in Hims & Hers Health's revenue and profit?

What is the market's earnings forecast for Hims & Hers Health next quarter?

What is the revenue and EPS growth rate for Hims & Hers Health year over year?

What were the key takeaways from Hims & Hers Health’s earnings call?

- **Revenue Growth**: Q4 2025 revenue up 28% YoY to $618M, driven by new specialties and 400% YoY international expansion.
- **GLP-1 Mitigation**: Non-GLP-1 offerings generate >80% of cash flow; 70% of Labs customers identify treatable risks.
- **International Ambition**: $1B+ annual international revenue target by 2030, with Eucalyptus acquisition for $1.15B.
- **AI & Innovation**: Conversational AI boosts engagement, YourBio at-home testing to launch in 2026.
- **Financial Health**: 2025 operating cash flow $300M, $929M cash on hand, 2026 EBITDA guidance $300M-$375M.

**【CEO Summary Section】**
- Revenue grew 28% YoY to $618M in Q4 2025, driven by expansion into new specialties (e.g., weight loss, Labs, menopause support) and international markets.
- Weight loss business, including GLP-1s, contributed significant growth, with subscribers growing 70% YoY in Q4. However, GLP-1s represent a small minority (under 10%) of total subscribers.
- International expansion via acquisitions (ZAVA, Livewell, Eucalyptus) targeted $1B+ in annual revenue by 2030, with 2025 international revenue up 400% YoY to $134M.
- Investing $300M+ in R&D and infrastructure for personalized treatments, AI, and wearables (e.g., YourBio's at-home blood testing).
- 2030 goals: $6.5B revenue, $1.3B adjusted EBITDA.

**【CFO Financial Commentary】**
- Full-year 2025 revenue: $2.35B (59% YoY growth), adjusted EBITDA: $318M (80% YoY growth), margin 14%.
- Q4 2025 adjusted EBITDA: $66M (11% margin), impacted by $65M headwind from weight loss shipping cadence changes.
- Marketing efficiency improved, with 39% of Q4 revenue allocated to marketing (down 7pts YoY).
- 2026 guidance: Revenue $2.7B-$2.9B (15%-24% YoY), adjusted EBITDA $300M-$375M (12% margin).
- Generated $300M operating cash flow in 2025, with $929M cash on hand.

**【Q&A Key Highlights】**
- **Regulatory Risk Mitigation**: Diversified revenue away from GLP-1s (non-GLP-1 offerings generate >80% of cash flow). 70% of Labs customers identify treatable health risks on platform.
- **Marketing Evolution**: Lower CAC through brand awareness (e.g., Super Bowl ad), higher LTV from personalized treatments (e.g., 80%+ testosterone level improvement in 2 months).
- **International Strategy**: Acquire Eucalyptus for $1.15B to expand into Australia, Japan, and Europe. Target 12-18 months to break even in new markets.
- **AI & Wearables**: Invest in conversational AI to increase engagement (e.g., 50%+ weight logging frequency in trials). YourBio's at-home testing to launch in 2026.


Hims & Hers Health, Inc. (HIMS) Q4 2025 Earnings Call Transcript

- **Record Growth**: Q3 2025 revenue surged 49% YoY to $600 million, driven by personalized solutions and new specialties like menopause and weight loss.
- **Strategic Expansion**: Launched lab testing and invested $1.1 billion in cash to accelerate international expansion (Canada, Europe) and verticalize compounding infrastructure.
- **Partnerships & Innovation**: Partnered with Novo Nordisk and GRAIL, reduced GLP-1 prices by 20%, and plans to launch longevity treatments in 2026.
- **Long-Term Vision**: On track to meet 2030 targets of $6.5 billion in revenue and $1.3 billion in EBITDA, despite near-term margin headwinds from investments.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 2025 revenue reached nearly $600 million, up 49% YoY, driven by personalized solutions and new specialties like weight loss and menopause care.
- **Strategic Initiatives**: Launched partnerships with Novo Nordisk (Wegovy) and GRAIL (multi-cancer early detection), and invested in verticalized compounding infrastructure to reduce costs and improve accessibility.
- **New Offerings**: Introduced low testosterone treatment, perimenopause/menopause support, and plans to launch comprehensive lab testing by year-end 2025. Microdosing options for compounded semaglutide were also added.
- **International Expansion**: Acquired Zava Global to enter U.K., Germany, France, Ireland, and Spain; preparing to launch in Canada in 2026.
- **Long-Term Vision**: Aims to become the largest global consumer health platform, with 2030 targets of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA.

**【CFO Financial Commentary】**
- **Profitability**: Adjusted EBITDA grew 50% YoY to $78 million, with margins above 13%. Marketing spend as a percentage of revenue declined 6pts YoY due to lower-cost channels and higher retention.
- **Gross Margin Pressure**: Declined 2pts QoQ to 74% due to shorter shipment cadences for weight loss products, but expects normalization in 2H 2026.
- **Cash Flow**: Generated $149 million in operating cash flow, with $1.1 billion in total cash and investments.
- **Investments**: Planning to expand operational footprint to over 1 million sq ft by year-end, and increase R&D in AI and diagnostics.

**【Q&A Highlights】**
- **Lab Testing & Longevity**: Launched whole-body lab testing before year-end, with a longevity specialty (peptides, GLP-1s) set to launch in 2026. Prices for compounded GLP-1s were reduced by 20% to expand accessibility.
- **Core Business Growth**: Despite near-term headwinds from sexual health transition, expects acceleration in 2H 2026 as daily solutions and multi-condition plans gain traction.
- **International Momentum**: Zava contributed $50 million+ in incremental revenue in Q3, with strong demand in Europe. Canada launch expected to capitalize on 2/3 of adults living with obesity.
- **Margin Outlook**: Anticipates temporary margin contraction in 2026 due to investments, but confident in long-term free cash flow generation.
- **Partnerships**: Actively negotiating with Novo Nordisk for Wegovy distribution, and exploring collaborations to bring advanced diagnostics and treatments to consumers.

Hims & Hers Health, Inc. (HIMS) Q3 2025 Earnings Call Transcript

- **Revenue Surge**: Q2 revenue up 73% YoY to $545 million, driven by 31% YoY subscriber growth to 2.4 million.
- **New Product Momentum**: At-home lab testing and hormonal health launches, with Canada expansion via generic semaglutide in 2026.
- **AI-Driven Innovation**: AI agents and data platform to enhance customer engagement, supported by $1.1 billion cash balance.
- **Global Ambitions**: 2030 targets of $6.5B revenue and $1.3B EBITDA, with ZAVA acquisition accelerating international growth.
- **Financial Resilience**: 15% EBITDA margin, $82M adjusted EBITDA, and $1.1B cash for strategic investments.

**【CEO Summary Section】**
- **Revenue Growth and Subscriber Expansion**: Q2 revenue reached $545 million (73% YoY growth), with subscribers increasing to 2.4 million (31% YoY). Key specialties like dermatology, oral weight loss, and daily sexual health grew over 55% YoY.
- **New Product Launches**: Launched at-home lab testing and hormonal health offerings, with plans to expand into longevity and global markets. Acquired ZAVA to accelerate European and Canadian expansion.
- **AI and Technology Strategy**: Introduced AI-powered personalized agents and a unified data platform, led by new CTO Mo Elshenawy, to enhance customer engagement and care delivery.
- **Global Ambitions**: Targeting 2030 goals of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA, with international expansion as a key growth lever.

**【CFO Financial Commentary】**
- **Financial Performance**: Adjusted EBITDA of $82 million (15% margin), driven by gross margin expansion to 76% and cost control. Free cash flow negative at $69 million due to strategic investments.
- **Key Metrics**: Monthly ARPU of $74 (down 13% QoQ due to GLP-1 offboarding). Weight loss specialty expected to generate $725 million in 2025, with oral offerings leading growth.
- **Investment Priorities**: Allocating capital to AI, lab testing, and international expansion, with a focus on 1-year payback periods for marketing investments.
- **Balance Sheet Strength**: $1.1 billion in cash post convertible debt offering, supporting M&A and organic growth.

**【Q&A Highlights】**
- **Weight Loss Segment**: Despite GLP-1 headwinds, oral and compounded semaglutide demand strong. 2025 target of $725 million remains intact, with generic semaglutide launch in Canada expected in 2026.
- **International Strategy**: ZAVA acquisition to support European and Canadian growth, with plans to replicate U.S. model in key markets like Brazil and Latin America.
- **AI and Lab Testing**: AI-driven agents to enhance customer retention and engagement. Lab testing to launch as standalone service, with potential for preventive care membership models.
- **Financial Discipline**: Maintaining capital allocation rigor, with severance and talent costs impacting Q2 EBITDA by $7 million. Free cash flow expected to turn positive in H2.


Hims & Hers Health, Inc. (HIMS) Q2 2025 Earnings Call Transcript

- **Revenue Growth Supercharged**: Q1 2025 revenue up 111% YoY to $586M, driven by weight loss ($725M+ target) and personalized solutions.
- **Profitability Soars**: Adjusted EBITDA tripled to $91M (16% margin), with monthly rev per sub up 50% to $84.
- **Strategic Wins**: Novo Nordisk partnership expands GLP-1 options; peptide lab acquisition positions for longevity care.
- **Long-Term Ambition**: $6.5B+ by 2030 via 5 pillars – personalization, specialty expansion, partnerships, global scale, and convenience.
- **Risk Management**: No insurance integration; focus on direct-to-consumer model with competitive pricing.

**【CEO Opening Remarks】**
- Q1 2025 revenue surged 111% YoY to $586 million, driven by expansion into new specialties (e.g., weight loss, menopause support) and personalized solutions adoption.
- Launched collaboration with Novo Nordisk to offer branded Wegovy, complementing existing oral and personalized GLP-1 options.
- Long-term vision: $6.5B+ revenue by 2030 through 5 growth pillars – personalization, specialty expansion, convenience, partnerships, and global scale.

**【CFO Financial Highlights】**
- Adjusted EBITDA reached $91 million (16% margin), up nearly 3x YoY.
- Monthly online revenue per subscriber climbed 50% YoY to $84, driven by weight loss and premium daily solutions.
- Gross margin declined 3pts QoQ due to GLP-1 scale, but expects improvement in Q2 with operational efficiencies.
- 2025 full-year guidance: $2.3-2.4B revenue (56-63% YoY growth), $295-335M EBITDA (13% margin).

**【Q&A Key Takeaways】**
- **Weight Loss Strategy**: Oral liraglutide adoption strong (300%+ YoY), branded Wegovy adds $725M+ annual target confidence.
- **Sexual Health Transition**: Daily multi-condition treatments now 40% of specialty, retention +10pts vs. on-demand users.
- **Partnership Risks**: Novo Nordisk supports personalized semaglutide use for clinical necessity, no caps on ratio of branded vs. custom dosing.
- **Longevity Play**: Acquired peptide facility to enable at-home lab testing for hormone, cardiovascular, and longevity biomarkers.
- **Insurance Strategy**: No plans to integrate insurance; focus on cash-pay model with prices below typical high-deductible co-pays.


Hims & Hers Health (HIMS)-5 May 25-2025 Q1 Earnings call transcript

- **Record Growth**: Q4 2024 revenue surged 95% YoY to $481 million, with 2.2 million subscribers (45% YoY). Weight loss specialty contributed $225 million, driven by oral solutions and personalized GLP-1 dosing.
- **Game-Changing Acquisitions**: Whole body lab testing and peptide manufacturing enable expansion into menopause, low testosterone, and metabolic health. Lab testing will offer low-cost biomarker insights for personalized care.
- **AI-Driven Innovation**: Investing in AI coaches, diagnostic tools, and 300+ personalized treatments. Aim to scale to thousands of treatments by leveraging verticalized infrastructure and data.
- **2025 Ambition**: Target $2.3-$2.4 billion revenue with 12%+ EBITDA margin. Launch liraglutide mid-year, expand sterile compounding, and integrate lab testing into 10,000+ daily patient visits.
- **Defensible Positioning**: 85%+ retention rate, 46% marketing efficiency, and vertical integration differentiate against competitors. No reliance on branded GLP-1 due to supply chain challenges.


**【CEO Summary Section】**
- **Revenue Growth & Market Expansion**: Q4 2024 revenue reached $481 million (YoY +95%), with full-year revenue of $1.5 billion (YoY +69%). Weight loss specialty contributed $225 million in 2024, driven by oral-based solutions and personalized GLP-1 dosing. Total subscribers exceeded 2.2 million (YoY +45%).
- **Strategic Acquisitions**: Acquired whole body lab testing facilities and a peptide manufacturing facility to expand personalized treatments for menopause, low testosterone, and metabolic health. Lab testing will enable proactive health monitoring and holistic treatment plans.
- **AI & Technology Integration**: Investing in AI-driven tools for 24/7 health coaching, diagnostic support, and follow-up care. Aim to expand personalized treatments from 300 to thousands of variations, leveraging verticalized infrastructure and data insights.
- **2025 Priorities**: Integrate lab testing, expand sterile compounding capacity, launch liraglutide in mid-2025, and explore peptide innovations. Focus on long-term retention with 85%+ subscriber retention rate.

**【CFO Financial Commentary】**
- **Profitability & Cash Flow**: Achieved GAAP net income of $26 million (Q4) and $126 million (FY2024), with free cash flow of $200 million. Adjusted EBITDA margin improved to 12% (FY2024). Q4 gross margin declined 2pts due to GLP-1 scaling, but expects recovery in Q2+2025.
- **2025 Outlook**: Revenue guidance of $2.3-$2.4 billion (YoY +56%-63%), with adjusted EBITDA of $270-$320 million. Weight loss specialty expected to contribute $725 million, excluding semaglutide. Marketing efficiency improved to 46% of revenue (FY2024), with 1-3pts leverage annually.

**【Q&A Highlights】**
- **GLP-1 Dynamics**: Personalized semaglutide will remain for clinical necessity, while oral solutions dominate at $165/month. Liraglutide launch in mid-2025 may face higher costs due to daily injections. Lab testing will expand into menopause and low testosterone.
- **Competitive Strategy**: Differentiate through high-touch care, affordability, and vertical integration. AI tools for lifestyle coaching and adherence support will enhance retention. No immediate plans for branded GLP-1 partnerships due to supply chain challenges.
- **Hers Growth**: Women's health specialties (dermatology, mental health) drive 30% of non-GLP-1 revenue. Oral weight loss solutions and liraglutide will expand Hers' reach in 2025.


Actual	-0.085	-0.34	-0.05	-0.08	-0.15	-0.08	-0.1	-0.09	-0.05	-0.05	-0.03	-0.04	0.01	0.05	0.06	0.32	0.11	0.2	0.17	0.06	0.08
Forecast	-0.1607	-0.1082	-0.0831	-0.0802	-0.0888	-0.0831	-0.0812	-0.1014	-0.0585	-0.0206	-0.0485	-0.0357	-0.0223	0.0103	0.0446	0.1112	0.1133	0.1209	0.1508	0.0943	0.0399
Surprise	+47.11%	-214.23%	+39.83%	+0.25%	-68.92%	+3.73%	-23.15%	+11.24%	+14.53%	-142.72%	+38.14%	-12.04%	+144.84%	+385.44%	+34.53%	+187.77%	-2.91%	+65.43%	+12.73%	-36.37%	+100.50%

HIMS

HIMS fundamentals

HIMS Q4 2025 Earnings

Earnings Call

You can ask Aime

HIMS

HIMS fundamentals

HIMS Q4 2025 Earnings

Earnings Call

HIMS Earnings Call Summary for Q4/20255:00 PM on Feb 23, 2026

HIMS Earnings Call Summary for Q3/20255:00 PM on Nov 3, 2025

HIMS Earnings Call Summary for Q2/20255:00 PM on Aug 4, 2025

HIMS Earnings Call Summary for Q1/20255:00 PM on May 5, 2025

HIMS Earnings Call Summary for Q4/20245:00 PM on Feb 24, 2025

You can ask Aime